A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Male or female participants between 40 and 80 years of age

• Diagnosis of moderate to moderately-severe osteoarthritis (OA) of either the knee or hip with respect to the following:

• Pain in one knee/hip over 3 months immediately before screening visit

• Use of non steroidal anti-inflammatory drugs (NSAIDs), acetaminophen (paracetamol) or any other analgesic for 3 or more days per week for at least 3 months prior to screening visit

• Clinical diagnosis of osteoarthritis of knee/hip for minimum 6 month duration prior to screening visit

• Therapeutic benefit with acetaminophen use with a score of ≥ 1 on 5-point categorical scale

• Radiological evidence of ≥ Grade 2 osteoarthritis according to Kellgren-Lawrence radiographic criteria

• Increased WOMAC Pain Subscale score of at least 20 % following untreated run-in period

• Moderate to moderately-severe self-reported pain on a 5-point categorical scale following untreated run-in period

• Historical self-reported positive therapeutic benefit with paracetamol use for osteoarthritis pain relief

Exclusion Criteria:

• History of surgery or major trauma to the study joint

• Clinically significant signs or symptoms of inflammation upon completion of run-in period

• Required ongoing use of analgesic therapy for other indications, anticoagulants, psychotherapeutic agents, aspirin at daily doses greater than 325 mg, statin-class hypolipidemic agents at doses that have not been stabilized, or other treatments know to interfere with pain perception

• History of hepatic or renal or liver or biliary disease or gastrointestinal surgery

• Participants with alanine aminotransferase (ALT) >2 times Upper Limit Normal (2xULN) and bilirubin > 1.5 times Upper Limit Normal (1.5xULN) (However, if direct bilirubin is <35% and fractioned, isolated bilirubin >1.5xULN is acceptable)

• Other arthritis type, fibromyalgia or collagen vascular disease or secondary OA of study joint or chronic pain condition